What is the cost of Zaltrap?
The cost of Zaltrap (ziv-aflibercept) can vary significantly depending on factors such as insurance coverage, dosage, and geographic location. For commercially insured patients, out-of-pocket costs may be reduced through assistance programs.
How can patients access financial assistance for Zaltrap?
Patients prescribed Zaltrap may be eligible for financial assistance programs. For instance, the Zaltrap Buy & Bill program offers co-pay savings for eligible commercially insured patients. Details on eligibility and enrollment for such programs can typically be found through the drug's manufacturer or specialty pharmacies.
What is Zaltrap used to treat?
Zaltrap is a targeted cancer therapy indicated for use in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease is metastatic and who have not had it worsen with prior treatment with an irinotecan-containing regimen [1]. It is also used in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab for patients with mCRC whose disease has not worsened with prior oxaliplatin-containing chemotherapy [1].
What is the mechanism of action for Zaltrap?
Zaltrap is a recombinant fusion protein consisting of the extracellular domains of human vascular endothelial growth factor (VEGF) receptors 1 and 2, fused to the Fc portion of human IgG1. It acts as a soluble decoy receptor that binds to VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby inhibiting their ability to bind to their native cell surface receptors. This process prevents tumor angiogenesis, the formation of new blood vessels that supply tumors with nutrients and oxygen, which is crucial for tumor growth and metastasis [1].
What are the potential side effects of Zaltrap?
Common side effects associated with Zaltrap therapy include diarrhea, fatigue, hypertension, and proteinuria [1]. More serious side effects can include gastrointestinal perforation, severe bleeding, impaired wound healing, and thrombotic events [1]. Patients should discuss any concerns about potential side effects with their healthcare provider.
When does Zaltrap's patent protection expire?
Information on specific patent expiry dates for Zaltrap is not readily available in this context. Patent expiration dates are critical for determining when generic or biosimilar versions of a drug may become available, potentially impacting cost and market competition. Resources like DrugPatentWatch.com can provide detailed patent information for pharmaceuticals [2].
How does Zaltrap compare to other colorectal cancer treatments?
Zaltrap is used in combination with established chemotherapy regimens like FOLFIRI and FOLFOX. Its role is to enhance the efficacy of these standard treatments by targeting angiogenesis. Other targeted therapies and immunotherapies are also used in the treatment of metastatic colorectal cancer, each with distinct mechanisms of action, efficacy profiles, and side effect considerations. The choice of treatment depends on the specific characteristics of the patient's cancer, prior treatments, and overall health status.
What is the recommended dosage and administration of Zaltrap?
The recommended dose of Zaltrap is 4 mg/kg administered intravenously over 60 minutes every two weeks as a combination therapy. It is administered before chemotherapy [1]. Dosage adjustments may be necessary based on patient tolerance and the occurrence of adverse events.
Sources:
[1] https://www.drugs.com/zaltrap.html
[2] https://drugpatentwatch.com/